Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects

This study has been completed.
Sponsor:
Collaborator:
Ann & Robert H Lurie Children's Hospital of Chicago
Information provided by:
Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:
NCT00004361
First received: October 18, 1999
Last updated: June 23, 2005
Last verified: January 2001
  Purpose

OBJECTIVES: I. Identify latent hypoparathyroidism in normocalcemic adult survivors with repaired conotruncal cardiac defects, by evaluating parathyroid gland secretory function after induced hypocalcemia.

II. Determine the relationship of parathyroid hormone secretion to microdeletions in the same region of chromosome 22q11 as found in patients with DiGeorge anomaly.


Condition Intervention
Hypoparathyroidism
Tetralogy of Fallot
Pulmonary Valve Stenosis
Conotruncal Cardiac Defects
Heart Defects, Congenital
Pulmonary Atresia
Drug: calcium gluconate
Drug: sodium citrate

Study Type: Observational
Study Design: Primary Purpose: Screening

Resource links provided by NLM:


Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment: 150
Study Start Date: July 1995
Detailed Description:

PROTOCOL OUTLINE:

Patients are given sodium citrate over a 2 hour infusion on day 1. Blood is drawn at times -30, -15, 0, and every 10 minutes thereafter during the infusion. On day 2, patients are given calcium gluconate over a 2 hour infusion. Blood is drawn at times -30, -15, 0, and every 10 minutes thereafter during the infusion.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Diagnostically shown repaired or palliated conotruncal cardiac defects, including tetralogy of Fallot with pulmonary stenosis or pulmonary atresia, truncus arteriosus, or interrupted aortic arch type B
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004361

Sponsors and Collaborators
Ann & Robert H Lurie Children's Hospital of Chicago
Investigators
Study Chair: Craig B. Langman Ann & Robert H Lurie Children's Hospital of Chicago
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00004361     History of Changes
Other Study ID Numbers: 199/11936, NU-553
Study First Received: October 18, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):
DiGeorge syndrome
cardiovascular and respiratory diseases
conotruncal cardiac defects
endocrine disorders
genetic diseases and dysmorphic syndromes
hypoparathyroidism
pulmonary valve stenosis
rare disease
tetralogy of Fallot

Additional relevant MeSH terms:
Hypoparathyroidism
Congenital Abnormalities
Heart Defects, Congenital
Pulmonary Atresia
Pulmonary Valve Stenosis
Tetralogy of Fallot
Cardiovascular Abnormalities
Cardiovascular Diseases
Endocrine System Diseases
Heart Diseases
Heart Valve Diseases
Parathyroid Diseases
Vascular Malformations
Ventricular Outflow Obstruction

ClinicalTrials.gov processed this record on October 23, 2014